<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19342">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855086</url>
  </required_header>
  <id_info>
    <org_study_id>BRNCNS0008</org_study_id>
    <secondary_id>NCI-2016-01165</secondary_id>
    <secondary_id>BRNCNS0008</secondary_id>
    <secondary_id>P30CA124435</secondary_id>
    <nct_id>NCT02855086</nct_id>
  </id_info>
  <brief_title>Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery</brief_title>
  <official_title>Open-Label Study Evaluating Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Neoplasms During Neurosurgical Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eben Rosenthal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase I/II trial studies the best dose of cetuximab-IRDye 800CW and how well it
      works in detecting tumors in patients with malignant glioma who are undergoing surgery.
      Cetuximab-IRDye 800CW is an optical imaging agent that may help detect tumor cells when a
      special camera is used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the efficacy of cetuximab-IRDye 800CW (cetuximab IRDye800) in
      intraoperatively identifying malignant glioma compared to surrounding normal central nervous
      system tissue, as measured by tumor-to-background ratio.

      SECONDARY OBJECTIVES:

      I. To determine the tolerability of the cetuximab IRDye800 as an imaging agent in subjects
      undergoing resection of malignant glioma.

      OUTLINE: This is a dose-escalation study of cetuximab-IRDye 800CW. Patients are assigned to
      1 of 2 cohorts.

      COHORT I: Patients receive cetuximab intravenously (IV) over 30 minutes and a lower dose of
      cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.

      COHORT II: Patients receive cetuximab IV over 30 minutes and a higher dose of cetuximab
      IRDye800 IV over 30 minutes to 1 hour on day 0.

      All patients undergo standard of care surgical resection of tumor on days 2-5.

      After completion of study, patients are followed up at days 10 and 30.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor to background ratio</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Tumor to background ratios will be generated from still images by comparing the relative fluorescence of normal and tumor tissue. The average fluorescence will be compared to the average fluorescence of the surrounding tissue using the paired student's T test for each specimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of grade 2 or greater adverse events graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Type, incidence, severity, seriousness, and study treatment relatedness of adverse events will be analyzed. Descriptive statistics for continuous data will include mean, standard deviation, median, minimum, and maximum values. Frequencies and percentages will be used to summarize categorical data.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Brain Neoplasm</condition>
  <condition>Malignant Glioma</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (cetuximab, lower dose cetuximab-IRDye 800, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cetuximab IV over 30 minutes and a lower dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.
All patients undergo standard of care surgical resection of tumor on days 2-5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (cetuximab, higher dose cetuximab-IRDye 800, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cetuximab IV over 30 minutes and a higher dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.
All patients undergo standard of care surgical resection of tumor on days 2-5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort 1 (cetuximab, lower dose cetuximab-IRDye 800, surgery)</arm_group_label>
    <arm_group_label>Cohort 2 (cetuximab, higher dose cetuximab-IRDye 800, surgery)</arm_group_label>
    <other_name>Chimeric Anti-EGFR Monoclonal Antibody</other_name>
    <other_name>Chimeric MoAb C225</other_name>
    <other_name>Chimeric Monoclonal Antibody C225</other_name>
    <other_name>Erbitux</other_name>
    <other_name>IMC-C225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab-IRDye 800CW</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort 1 (cetuximab, lower dose cetuximab-IRDye 800, surgery)</arm_group_label>
    <arm_group_label>Cohort 2 (cetuximab, higher dose cetuximab-IRDye 800, surgery)</arm_group_label>
    <other_name>Cetuximab-IRDye 800</other_name>
    <other_name>Cetuximab-IRDye800</other_name>
    <other_name>Cetuximab-IRDye800CW</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Surgery</intervention_name>
    <description>Undergo tumor resection</description>
    <arm_group_label>Cohort 1 (cetuximab, lower dose cetuximab-IRDye 800, surgery)</arm_group_label>
    <arm_group_label>Cohort 2 (cetuximab, higher dose cetuximab-IRDye 800, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Cohort 1 (cetuximab, lower dose cetuximab-IRDye 800, surgery)</arm_group_label>
    <arm_group_label>Cohort 2 (cetuximab, higher dose cetuximab-IRDye 800, surgery)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with suspected brain tumors undergoing surgical removal as their standard of
             care will be eligible; these may include subjects status post chemotherapy and/or
             radiation or subjects who have undergone diagnostic biopsy for their original
             diagnosis and are felt to be candidates for resection

          -  Subjects must be eligible for resection as determined by the operating surgeon

          -  Planned standard of care surgery

          -  Life expectancy of more than 12 weeks

          -  Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group
             (ECOG)/Zubrod level 1

          -  Hemoglobin &gt;= 9 gm/dL

          -  Platelet count &gt;= 100,000/mm^3

          -  Magnesium, potassium and calcium &gt; the lower limit of normal per institution normal
             lab values

          -  Thyroid-stimulating hormone (TSH) &lt; 13 micro international units/mL

        Exclusion Criteria:

          -  Received an investigational drug within 30 days prior to first dose of cetuximab
             IRDye800

          -  Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive
             heart failure (CHF); significant liver disease; or unstable angina within 6 months
             prior to enrollment

          -  History of infusion reactions to cetuximab or other monoclonal antibody therapies

          -  Pregnant or breastfeeding

          -  Subjects who have a serious reaction with the test/loading cetuximab dose for which
             they were not able to receive the full dose

          -  Evidence of QT prolongation on pretreatment electrocardiogram (ECG) (greater than 440
             ms in males or greater than 450 ms in females)

          -  Lab values that in the opinion of the primary surgeon would prevent surgical
             resection

          -  Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide,
             amiodarone, sotalol) antiarrhythmic agents

          -  Subjects not deemed to be appropriate candidates for optimal resection of tumor based
             on location, involvement of eloquent brain, satellite lesions, or other factors not
             specifically listed here
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eben Rosenthal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alifia Hasan</last_name>
      <phone>650-721-6509</phone>
      <email>alifia@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Gordon Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eben Rosenthal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 6, 2016</lastchanged_date>
  <firstreceived_date>August 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Eben Rosenthal</investigator_full_name>
    <investigator_title>Professor of Otolaryngology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
